伍政宇;罗楚铭;贾婷婷;舒跃龙;

• 1:中山大学公共卫生学院(深圳)

摘要(Abstract)：

新型冠状病毒（SARS-CoV-2）引发新型冠状病毒肺炎（COVID-19）全球大流行。由于SARS-CoV-2生物安全管理的要求，高效制备获得高滴度的新型冠状病毒假病毒对基于S蛋白研发疫苗、中和抗体、病毒入侵抑制剂药物以及人群血清学调查等十分重要。本研究基于慢病毒系统，对制备新型冠状病毒假病毒过程中的重要参数进行优化，用Western Blot检测假病毒S蛋白和p24蛋白的表达及假病毒包装情况，用荧光素酶报告系统检测假病毒感染入侵效率。利用制备好的假病毒对恢复期血浆的中和抗体水平进行检测。结果显示骨架质粒与野生型Spike质粒为2∶1比例，在转染后48h收集上清为SARS-CoV-2野生型假病毒包装的最佳条件。与野生型相比，恢复期血浆对四种突变株的中和抗体滴度均降低，对B.1.351株中和能力最弱，B.1.617.2株其次，重型患者恢复期血浆对野生型和突变株的中和抗体滴度高于轻型与普通型患者。本研究优化了新型冠状病毒假病毒包装的实验室条件，评估了COVID-19患者恢复期血浆对野生型及四种突变株的中和抗体水平，提示未来对突变株的免疫逃逸进一步加强监测的重要性。

关键词(KeyWords)： 新型冠状病毒;假病毒;中和抗体

Abstract:

Keywords:

基金项目(Foundation): 深圳市科技计划技术攻关重点项目(项目号：JSGG20200225152008136)，题目：基于免疫原优化的广谱冠状病毒疫苗研发~~

作者(Authors): 伍政宇;罗楚铭;贾婷婷;舒跃龙;

DOI: 10.13242/j.cnki.bingduxuebao.004126

参考文献(References)：

• [1] Wu F,Zhao S,Yu B,Chen Y M,Wang W,Song Z G,Hu Y,Tao Z W,Tian J H,Pei Y Y,Yuan M L,Zhang Y L,Dai F H,Liu Y,Wang Q M,Zheng J J,Xu L,Holmes E C,Zhang Y Z. A new coronavirus associated with human respiratory disease in China[J].Nature,2020,579(7798):265-269.
• [2] Zhou P,Yang X L,Wang X G,Hu B,Zhang L,Zhang W,Si H R,Zhu Y,Li B,Huang C L,Chen H D,Chen J,Luo Y,Guo H,Jiang R D,Liu M Q,Chen Y,Shen X R,Wang X,Zheng X S,Zhao K,Chen Q J,Deng F,Liu L L,Yan B,Zhan F X,Wang Y Y,Xiao G F,Shi Z L. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,579(7798):270-273.
• [3] Worldometer. COVID-19 coronavirus pandemic[EB/OL]. https：//www.worldometers.info/coronavirus.
• [4] Shang J,Wan Y,Luo C,Ye G,Geng Q,Auerbach A,Li F. Cell entry mechanisms of SARS-CoV-2[J].Proc Natl Acad Sci U S A,2020,117(21):11727-11734.
• [5] Hu J,Gao Q,He C,Huang A,Tang N,Wang K.Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2[J]. Genes Dis,2020,7(4):551-557.
• [6] Nie J,Li Q,Wu J,Zhao C,Hao H,Liu H,Zhang L,Nie L,Qin H,Wang M,Lu Q,Li X,Sun Q,Liu J,Fan C,Huang W,Xu M,Wang Y. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay[J]. Nat Protoc,2020,15(11):3699-3715.
• [7] Li Q,Liu Q,Huang W,Li X,Wang Y. Current status on the development of pseudoviruses for enveloped viruses[J/OL]. Rev Med Virol,2018,28(1):e1963.
• [8] Hyseni I,Molesti E,Benincasa L,Piu P,Casa E,Temperton N J, Manenti A, Montomoli E.Characterisation of SARS-CoV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live Virus-based micro neutralisation assays[J]. Viruses,2020,12(9):1011.
• [9] Chen M,Zhang X E. Construction and applications of SARS-CoV-2 pseudoviruses:a mini review[J]. Int J Biol Sci,2021,17(6):1574-1580.
• [10]Yang R,Huang B,A R,Li W,Wang W,Deng Y,Tan W. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro[J]. Biosaf Health,2020,2(4):226-231.
• [11]Hu J,Peng P,Wang K,Fang L,Luo F Y,Jin A S,Liu B Z,Tang N,Huang A L. Emerging SARS-CoV-2variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies[J]. Cell Mol Immunol,2021,18(4):1061-1063.
• [12]Ding C,He J,Zhang X,Jiang C,Sun Y,Zhang Y,Chen Q,He H,Li W,Xie J,Liu Z,Gao Y. Crucial mutations of Spike protein on SARS-CoV-2 evolved to variant strains escaping neutralization of convalescent plasmas and RBD-Specific Monoclonal antibodies[J].Front Immunol,2021,12:693775.
• [13]Zhang S,Qiao S,Yu J,Zeng J,Shan S,Tian L,Lan J,Zhang L,Wang X. Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARSCoV-2 evolution[J]. Nat Commun,2021,12(1):1607.
• [14]Yang L,Pei R J,Li H,Ma X N,Zhou Y,Zhu F H,He P L,Tang W,Zhang Y C,Xiong J,Xiao S Q,Tong X K,Zhang B,Zuo J P. Identification of SARSCoV-2 entry inhibitors among already approved drugs[J]. Acta Pharmacol Sin,2021,42(8):1347-1353.
• [15]Ma Y,Mao G,Wu G,Chen M,Qin F,Zheng L,Zhang X E. Dual-Fluorescence labeling pseudovirus for Real-Time imaging of single SARS-CoV-2 entry in respiratory epithelial cells[J]. ACS Appl Mater Interfaces,2021,13(21):24477-24486.
• [16]Ou X,Liu Y,Lei X,Li P,Mi D,Ren L,Guo L,Guo R,Chen T,Hu J,Xiang Z,Mu Z,Chen X,Chen J,Hu K,Jin Q,Wang J,Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV[J]. Nat Commun,2020,11(1):1620.
• [17]Li T,Xue W,Zheng Q,Song S,Yang C,Xiong H,Zhang S,Hong M,Zhang Y,Yu H,Zhang Y,Sun H,Huang Y,Deng T,Chi X,Li J,Wang S,Zhou L,Chen T,Wang Y,Cheng T,Zhang T,Yuan Q,Zhao Q,Zhang J,McLellan J S,Zhou Z H,Zhang Z,Li S,Gu Y,Xia N. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants[J]. Nat Commun,2021,12(1):5652.
• [18]Crawford K H D,Eguia R,Dingens A S,Loes A N,Malone K D,Wolf C R,Chu H Y,Tortorici M A,Veesler D,Murphy M,Pettie D,King N P,Balazs A B,Bloom J D. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays[J]. Viruses,2020,12(5):513.
• [19]Stillman E A,Rose J K,Whitt M A. Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins[J]. J Virol,1995,69(5):2946-2953.
• [20]Whitt M A. Generation of VSV pseudotypes using recombinantΔG-VSV for studies on virus entry,identification of entry inhibitors,and immune responses to vaccines[J]. J Virol Methods,2010,169(2):365-374.
• [21]Nie J,Li Q,Wu J,Zhao C,Hao H,Liu H,Zhang L,Nie L,Qin H,Wang M,Lu Q,Li X,Sun Q,Liu J,Fan C,Huang W,Xu M,Wang Y. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2[J]. Emerg Microbes Infect, 2020, 9(1):680-686.
• [22]Xiong H-L,Wu Y-T,Cao J-L,Yang R,Liu Y-X,Ma J,Qiao X-Y,Yao X-Y,Zhang B-H,Zhang Y-L,Hou W-H,Shi Y,Xu J-J,Zhang L,Wang S-J,Fu B-R,Yang T,Ge S-X,Zhang J,Yuan Q,Huang B-Y,Li ZY,Zhang T-Y,Xia N-S. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus(VSV)pseudovirus and ACE2-overexpressing BHK21 cells[J]. Emerg Micro&Infect,2020,9(1):2105-2113.
• [23]Hoffmann M,Kleine-Weber H,Schroeder S,Krüger N,Herrler T,Erichsen S,Schiergens T S,Herrler G,Wu N H, Nitsche A, Müller M A, Drosten C,P?hlmann S. SARS-CoV-2 cell entry depends on ACE2and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J/OL]. Cell,2020,181(2):271-280.e278.
• [24]Walls A C, Park Y J, Tortorici M A, Wall A,McGuire A T,Veesler D. Structure,Function,and Antigenicity of the SARS-CoV-2 Spike Glycoprotein[J/OL]. Cell,2020,181(2):281-292.e286.
• [25]Zheng Y, Larragoite E T, Williams E, Lama J,Cisneros I,Delgado J C,Slev P,Rychert J,Innis E A,Coiras M,Rondina M T,Spivak A M,Planelles V.Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions[J]. Virol J,2021,18(1):1.
• [26]Zhang C,Wang Y,Zhu Y,Liu C,Gu C,Xu S,Wang Y,Zhou Y,Wang Y,Han W,Hong X,Yang Y,Zhang X,Wang T,Xu C,Hong Q,Wang S,Zhao Q,Qiao W,Zang J,Kong L,Wang F,Wang H,Qu D,Lavillette D, Tang H, Deng Q, Xie Y, Cong Y,Huang Z. Development and structural basis of a twoMAb cocktail for treating SARS-CoV-2 infections[J].Nat Commun,2021,12(1):264.
• [27]Chen X,Chen Z,Azman A S,Sun R,Lu W,Zheng N,Zhou J,Wu Q,Deng X,Zhao Z,Chen X,Ge S,Yang J,Leung D T,Yu H. Neutralizing antibodies against Severe Acute Respiratory Syndrome Coronavirus2(SARS-CoV-2)variants induced by natural infection or vaccination:A systematic review and pooled analysis[J]. Clin Infect Dis,2022,74(4):734-742.
• [28]Moore M J,Dorfman T,Li W,Wong S K,Li Y,Kuhn J H,Coderre J,Vasilieva N,Han Z,Greenough T C,Farzan M,Choe H. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2[J]. J Virol,2004,78(19):10628-10635.
• [29]Luo H,Jia T,Chen J,Zeng S,Qiu Z,Wu S,Li X,Lei Y,Wang X,Wu W,Zhang R,Zou X,Feng T,Ding R,Zhang Y,Chen Y Q,Sun C,Wang T,Fang S, Shu Y. The characterization of disease severity associated IgG subclasses response in COVID-19patients[J]. Front Immunol,2021,12:632814.
• [30]WHO. Variants of concern[EB/OL]. https：//www.who.int/en/activities/tracking-SARS-CoV-2-variants.
• [31]Du L,Zhao G,Zhang X,Liu Z,Yu H,Zheng B J,Zhou Y,Jiang S. Development of a safe and convenient neutralization assay for rapid screening of influenza HAspecific neutralizing monoclonal antibodies[J]. Biochem Biophys Res Commun,2010,397(3):580-585.
• [32]Schmidt F,Weisblum Y,Muecksch F,Hoffmann H H, Michailidis E, Lorenzi J C C, Mendoza P,Rutkowska M,Bednarski E,Gaebler C,Agudelo M,Cho A,Wang Z,Gazumyan A,Cipolla M,Caskey M,Robbiani D F, Nussenzweig M C, Rice C M,Hatziioannou T,Bieniasz P D. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses[J/OL]. J Exp Med,2020,217(11):e20201181.
• [33]Zhao G,Du L,Ma C,Li Y,Li L,Poon V K,Wang L,Yu F,Zheng B J,Jiang S,Zhou Y. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERSCoV[J]. Virol J,2013,10:266.
• [34]Wang H,Yang P,Liu K,Guo F,Zhang Y,Zhang G,Jiang C. SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway[J]. Cell Res,2008,18(2):290-301.
• [35]Garcia-Beltran W F,Lam E C,Astudillo M G,Yang D,Miller T E,Feldman J,Hauser B M,Caradonna T M,Clayton K L,Nitido A D,Murali M R,Alter G,Charles R C,Dighe A,Branda J A,Lennerz J K,Lingwood D,Schmidt A G,Iafrate A J,Balazs A B.COVID-19-neutralizing antibodies predict disease severity and survival[J]. Cell,2021,184(2):476-488e411.
• [36]Tea F,Ospina Stella A,Aggarwal A,Ross Darley D,Pilli D,Vitale D,Merheb V,Lee F X Z,Cunningham P,Walker G J,Fichter C,Brown D A,Rawlinson W D,Isaacs S R,Mathivanan V,Hoffmann M,P?hlman S,Mazigi O,Christ D,Dwyer D E,Rockett R J,Sintchenko V,Hoad V C,Irving D O,Dore G J,Gosbell I B,Kelleher A D,Matthews G V,Brilot F,Turville S G. SARS-CoV-2 neutralizing antibodies:Longevity, breadth, and evasion by emerging viral variants[J/OL]. PLoS Med,2021,18(7):e1003656.
• [37]Trombetta C M,Marchi S,Viviani S,Manenti A,Benincasa L, Ruello A, Bombardieri E, Vicenti I,Zazzi M, Montomoli E. Serum neutralizing activity against B. 1.1.7,B. 1.351,and P. 1 SARS-CoV-2variants of concern in hospitalized COVID-19 patients[J]. Viruses,2021,13(7),1347.
• [38]Tada T, Zhou H, Dcosta B M, Samanovic M I,Mulligan M J,Landau N R. Partial resistance of SARSCoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera[J]. iScience,2021,24(11):103341.
• [39]Bates T A,Leier H C,Lyski Z L,McBride S K,Coulter F J,Weinstein J B,Goodman J R,Lu Z,Siegel S A R,Sullivan P,Strnad M,Brunton A E,Lee D X,Adey A C,Bimber B N,O'Roak B J,Curlin M E,Messer W B,Tafesse F G. Neutralization of SARSCoV-2 variants by convalescent and BNT162b2vaccinated serum[J]. Nat Commun,2021,12(1):5135.
• [40]Cele S,Jackson L,Khan K,Khoury D S,MoyoGwete T,Tegally H,Scheepers C,Amoako D,Karim F, Bernstein M, Lustig G, Archary D, Smith M,Ganga Y,Jule Z,Reedoy K,Cromer D,San J E,Hwa S H,Giandhari J,Blackburn J M,Gosnell B I,Karim S S A,Hanekom W,von Gottberg A,Bhiman J,Lessells R J,Moosa M S,Davenport M P,de Oliveira T,Moore P L,Sigal A. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2elicited neutralization and requires ACE2 for infection[J]. medRxiv,2021.12.08.21267417.
• [41]Zhang L,Li Q,Liang Z,Li T,Liu S,Cui Q,Nie J,Wu Q,Qu X,Huang W,Wang Y. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron[J]. Emerg Microbes Infect,2021:1-11.
• [42]Cao Y,Wang J,Jian F,Xiao T,Song W,Yisimayi A,Huang W,Li Q,Wang P,An R,Wang J,Wang Y,Niu X,Yang S,Liang H,Sun H,Li T,Yu Y,Cui Q,Liu S,Yang X,Du S,Zhang Z,Hao X,Shao F,Jin R,Wang X,Xiao J,Wang Y,Xie X S. B.1.1.529escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes[J]. BioRxiv,2021.12.07.470392.
• [43]Lu L,Mok B W,Chen L L,Chan J M,Tsang O T,Lam B H,Chuang V W,Chu A W,Chan W M,Ip J D,Chan B P,Zhang R,Yip C C,Cheng V C,Chan K H,Jin D Y,Hung I F,Yuen K Y,Chen H,To K K.Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients[J].Clin Infect Dis,2021:ciab1041.